Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1050-1062

  Flamant, F ^a   Rodary, C ^a   Rey, A ^a   Praquin, M T ^a   Sommelet, D ^b   Quintana, E ^c   Theobald, S ^a   Brunat Mentigny, M ^d   Otten, J ^e   Voute P A ^f   Habrand, J L ^a   Martelli, H ^g   Barrett, A ^h   Terrier Lacombe, M J ^a   Oberlin, O ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c INSTITUT CURIE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

Chemotherapy; Rhabdomyosarcoma

Indexed keywords

DACTINOMYCIN; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; RHABDOMYOSARCOMA; SURVIVAL RATE; TREATMENT PLANNING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DACTINOMYCIN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; QUALITY OF LIFE; RHABDOMYOSARCOMA; TREATMENT OUTCOME; UROGENITAL NEOPLASMS; VINCRISTINE;

EID: 0032102857     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00024-0     Document Type: Article

References (29)

1. Young J.L., Miller R.W. Incidence of malignant tumours in United States children. J Pediatr. 86:1975;254-258.
2. Donaldson S.S. The value of adjuvant chemotherapy in the management of sarcomas in children. Cancer. 55:1985;2184-2197.
3. Flamant F., Hill C. The improvement in survival associated with combined chemotherapy in childhood rhabdomyosarcoma. A historical comparison of 345 patients treated in the same center. Cancer. 53:1984;2417-2421.
4. Heyn R, Raney RB, Hays DM, et al. Late effects of therapy in patients with paratesticular rhabdomyosarcoma. J Clin Oncol 1992, 10, 614-623.
5. Heyn R, Ragab A, Raney RB, et al. Late effects of therapy in orbital rhabdomyosarcoma in children. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 1986, 57, 1738-1743.
6. Flamant F, Sarrazin D, Schwaab G, Delon E, Lemerle J. Les séquelles tardives des traitements locaux curateurs dans les tumeurs de la sphère ORL chez l'enfant. In Leroux-Robert J, Guerrier Y, eds. Actualités de Carcinologie Cervico-faciale. Paris, Masson, 1981, 109-120.
7. Rodary C, Rey A, Olive O, et al. Prognostic factors in 281 children with non metastatic rhabdomyosarcoma at diagnosis. Med Ped Oncol 1988, 16, 71-77.
8. Flamant F, Rodary C, Voute PA, et al. Primary chemotherapy in the treatment of rhabdomyosarcoma in children: trial of the International Society of Pediatric Oncology (SIOP). Preliminary results. Radiother Oncol 1985, 3, 227-236.
9. DeKraker J., Voute P.A. Ifosfamide, Mesna and vincristine in paediatric oncology. Cancer Treat Rev. 10:1983;165-166.
10. Stuart-Harris R, Harper PG, Kay SB, Wiltshaw E. High dose alkylation therapy using ifosfamide with Mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1983, 11, 69-72.
11. Hildgard P., Herdrich K., Brade W. Ifosfamide current aspect and perspectives. Cancer Treat Rev. 10:1983;183-192.
12. Newton WA, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification. An Intergroup Rhabdomyosarcoma study. Cancer 1995, 76, 1073-1085.
13. Rodary C, Flamant F, Donaldson SS, for the SIOP IRS Committee. An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP). Med Ped Oncol 1989, 17, 210-215.
14. Donaldson SS, Draper GJ, Flamant F, et al. Topography of childhood tumours pediatric coding system. Ped Hematol Oncol 1986, 3, 249-258.
15. Kaplan E.S., Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 53:1958;457-480.
16. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977, 35, 1-39.
17. Cox D.R. Regression models and life table. J R Stat Soc (B). 34:1972;187-220.
18. Suarez A, McDowell H, Niaudet P, et al. Long term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumours: an International Society of Pediatric Oncology report. J Clin Oncol 1991, 9, 2177-2182.
19. Maurer HM, Gehan EA, Beltangady M, et al. The Intergroup Rhabdomyosarcoma Study II. Cancer 1993, 71, 1904-1922.
20. Koscielnak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German cooperative soft tissue sarcoma study. Cancer 1992, 70, 2557-2567.
21. Crist W, Gehan EA, Ragab AH, et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 13, 610-630.
22. Rodary C, Flamant F, Maurer H, et al. Initial lymphadenectomy is not necessary in localised completely resected paratesticular rhabdomyosarcoma. Med Ped Oncol 1992, 20, 430.
23. Rousseau P, Flamant F, Quintana E, et al. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumours of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study. J Clin Oncol 1994, 12, 516-521.
24. Raney B, Kollath J, Anderson J, Warham M, Maurer H. Late effects of therapy for patients with primary orbital rhabdomyosarcoma: a report from Intergroup Rhabdomyosarcoma Study (IRS-III, 1984-1991). Third International Congress on Soft Tissue Sarcoma in Children and Adolescents. Stuttgart, 1997, 80.
25. Benk V, Rodary C, Flamant F, et al. Parameningeal rhabdomyosarcoma. Results of an international workshop. Int J Radiat Oncol Biol Phys 1996, 36, 534-540.
26. Godzinski J, Flamant F, Rey A, et al. Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected malignant mesenchymal tumours in children: SIOP 84 malignant mesenchymal tumours study. Med Ped Oncol 1994, 22, 22-26.
27. Newton W, Edward E, Hamoudi A, et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcomas Studies I and II: clinicopathologic correlation. J Clin Oncol 1988, 6, 67-75.
28. Harms D., Schmidt D., Treuner J. Soft-tissue sarcoma in childhood. A study of 262 cases including 169 cases of rhabdomyosarcoma. Z Kinderchir. 40:1985;140-145.
29. Newton WA, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcoma and related sarcomas. Pathologic aspects and proposals for a new classification. An Intergroup Rhabdomyosarcoma Study. Cancer 1995, 76, 1073-1085.